Skip to main content
Article thumbnail
Location of Repository

A Novel Information Retrieval Model for High-Throughput Molecular Medicine Modalities

By Firas H. Wehbe, Steven H. Brown, Pierre P. Massion, Cynthia S. Gadd, Daniel R. Masys and Constantin F. Aliferis

Abstract

Significant research has been devoted to predicting diagnosis, prognosis, and response to treatment using high-throughput assays. Rapid translation into clinical results hinges upon efficient access to up-to-date and high-quality molecular medicine modalities

Topics: Methodology
Publisher: Libertas Academica
OAI identifier: oai:pubmedcentral.nih.gov:2664697
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma.
    2. (2002). A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. New England
    3. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    4. (2007). An agent- and ontologybased system for integrating public gene, protein, and disease databases.
    5. (2004). An object model and database for functional genomics.
    6. (2005). An overview of the design and methods for retrieving high-quality studies for clinical care.
    7. (1998). Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler-Najjar type I disease.
    8. (2006). Converting a breast cancer microarray signature into a high-throughput diagnostic test.
    9. (1998). Current approaches to the management of non-Hodgkin’s lymphoma.
    10. (2006). Desiderata for domain reference ontologies in biomedicine.
    11. (2007). Diagnostics. Amid debate, gene-based cancer test approved.
    12. (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profi ling and supervised machine learning.
    13. (2000). Distinct types of diffuse large B-cell lymphoma identifi ed by gene expression profi ling.
    14. Drug Administration—Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels—http://www.fda.gov/cder/ genomics/genomic_biomarkers_table.htm—Last Update:
    15. (2004). Editing description logic ontologies with the protege-owl plugin.
    16. (2005). Epidermal growth factor receptor mutations and gene amplifi cation in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefi tinib trials.
    17. (2006). Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer.
    18. (2006). FuGE: Functional Genomics Experiment Object Model.
    19. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.
    20. (2000). Gene ontology: tool for the unifi cation of biology. The Gene Ontology Consortium.
    21. (2004). Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
    22. (2003). Indexing pharmacogenetic knowledge on the World Wide Web.
    23. (2006). Microarray analysis and tumor classifi cation.
    24. (2001). Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.
    25. (1999). Molecular Classifi cation of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring.
    26. (2007). NCBI GEO: mining tens of millions of expression profi les—database and tools update.
    27. (2007). NCI Thesaurus: a semantic model integrating cancer-related clinical and molecular information.
    28. Non-Hodgkin’s Lymphoma Prognostic Factors Project 1993, “A predictive model for aggressive non-Hodgkin’s lymphoma.
    29. (2006). On the Toxicity of Chemotherapy for Breast Cancer-the Need for Vigilance.
    30. (2007). Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profi les.
    31. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform.
    32. (2006). ONTOFUSION: ontology-based integration of genomic and clinical databases.
    33. (2002). Ontology development for a pharmacogenetics knowledge base.
    34. (2004). OWL Web Ontology Language Overview.
    35. (2004). Part-of relations in anatomy ontologies: a proposal for RDFS and OWL formalisations.
    36. (2006). Pharmacogenomics: from bedside to clinical practice.
    37. (2001). Phases of biomarker development for early detection of cancer.
    38. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    39. (2003). Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment.
    40. (2004). RAD and the RAD StudyAnnotator: an approach to collection, organization and exchange of all relevant information for high-throughput gene expression studies.
    41. (2005). Relations in biomedical ontologies.
    42. (2005). Roadmap for developing and validating therapeutically relevant genomic classifi ers.
    43. (2004). Submission of microarray data to public repositories.
    44. (2005). Text Categorization Models for High-Quality Article Retrieval in Internal Medicine.
    45. (2003). The challenge of molecular medicine: complexity versus Occam’s razor.
    46. (2005). The clinical bioinformatics ontology: a curated semantic network utilizing RefSeq information.
    47. (2003). The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice.
    48. (2002). The use of molecular profi ling to predict survival after chemotherapy for diffuse largeB-cell lymphoma.
    49. (2006). Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.